Interview: Xu Hang – CEO, Mindray, China
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
Address: Mindray Building, Keji 12th Road South, High-tech Industrial Park, Nanshan, Shenzhen 518057, P. R. China.,China
Tel: +86 (755) 26582888
Web: http://www.mindray.com/main/index.jsp
Mindray was founded in 1991 in Shenzhen, China, with a mission to deliver high-quality, competitively priced medical devices to make healthcare more accessible and affordable around the world. Over the last 18 years, Mindray has become a leading developer, manufacturer and marketer of medical devices worldwide. According to Frost & Sullivan, in 2006 Mindray attained a leading market share in China both by units sold and revenue for the sale of patient monitoring devices. Mindray also holds a leading market share in China in the three-part differentiation hematology analyzer, biochemistry analyzer and black and white ultrasound imaging system segments.
Our success has been deeply rooted in our commitment to invest approximately 10% of our revenues into R&D every year. With more than 1,530 engineers on staff, Mindray has built a world-class platform that capitalizes on low-cost China based R&D operations and a culture that is driven by ingenuity, and both individual and team performance. Mindray currently offers more than 40 products across three business segments including patient monitoring devices and life support products, in-vitro diagnostic instruments and medical imaging systems. Mindray expects to continue to introduce six to eight new products each year to broaden market reach. Mindray is confident that our growing comprehensive portfolio of high-quality, affordable products will allow the company to continue gaining market share both domestically and internationally.
In China, Mindray has distributed products to over 40,000 hospitals, clinics, and healthcare facilities. Outside China, Mindray has sold devices in over 190 countries. Mindray began exporting our products for the first time in 2000; and in the second half of 2007, revenues generated from international markets exceeded domestic revenues for the first time in Mindray’s operating history.
By June 2009, Mindray had a total of approximately 5,600 employees worldwide, and Mindray is expanding its distribution, sales and service network to bring products closer to end users. Mindray currently has 29 branch companies in major cities of China, as well as 12 overseas subsidiaries in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Milan, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver.
Mindray’s American Depositary Shares (ADSs) are listed on the New York Stock Exchange (NYSE) under the symbol MR.
patient monitoring, diagnostics and ultrasound imaging systems
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech,…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Elpiscience filing for a Hong Kong IPO after US$250M in financing, Zhejiang Medicine planning an HKEX spin-off for ADC…
Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s…
China is rapidly maturing into a global hub for innovation, offering speed, scale, and cost advantages in clinical trials that few markets can match. Andy Liu, Managing Director China for…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive…
See our Cookie Privacy Policy Here
